Magouliotis Dimitrios E, Minervini Fabrizio, Cioffi Ugo, De Simone Matilde, Patrini Davide, Scarci Marco
Department of Cardiac Surgery Research, Lankenau Institute for Medical Research, Main Line Health, Wynnewood, PA 19096, USA.
Luzern Kanton Hospital, 6000 Luzern, Switzerland.
Cells. 2025 Apr 12;14(8):585. doi: 10.3390/cells14080585.
Malignant pleural mesothelioma (MPM) is an aggressive cancer of the pleural lining, primarily associated with asbestos exposure. Despite advancements in multimodal treatment, patient survival remains poor. Epithelial-mesenchymal transition (EMT) has emerged as a crucial process driving MPM pathogenesis, metastasis, and resistance to therapy. This review explores the molecular mechanisms underlying EMT in MPM, including key signaling pathways such as TGF-β, Wnt/β-catenin, and PI3K/Akt. We also discuss the diagnostic and prognostic significance of EMT-related biomarkers and emerging targeted therapies aimed at reversing EMT or exploiting EMT-induced vulnerabilities. Additionally, recent clinical trials, including the MARS 2 trial, are reviewed to provide insight into the evolving treatment landscape.
恶性胸膜间皮瘤（MPM）是一种侵袭性的胸膜内衬癌症，主要与接触石棉有关。尽管多模式治疗取得了进展，但患者生存率仍然很低。上皮-间质转化（EMT）已成为驱动MPM发病机制、转移和治疗耐药性的关键过程。本综述探讨了MPM中EMT的分子机制，包括TGF-β、Wnt/β-连环蛋白和PI3K/Akt等关键信号通路。我们还讨论了EMT相关生物标志物的诊断和预后意义，以及旨在逆转EMT或利用EMT诱导的脆弱性的新兴靶向治疗。此外，还对包括MARS 2试验在内的近期临床试验进行了综述，以深入了解不断演变的治疗格局。
